Previous 10 | Next 10 |
Ines Dahne-Steuber named as chief operating officer Darya Chudova promoted to chief technology officer Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the expansion of its leadership team with the addition of Ines Dahne-Steuber as chief ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report additional data from its pivotal ECLIPSE study at Digestive Disease Week (DDW) on Tuesday, May 9, 2023. The company will host a webcast and conference call with primary investigators of the st...
2023-04-29 04:20:36 ET Summary Demographic trends are powerful and experience little impact from economic cycles. As the Millennial generation enters middle age and surpasses the number of Baby Boomers, the demand for medical screening and testing will increase. Exact Sciences...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming BofA Securities 2023 Healthcare Conference in Las Vegas, Nevada. Guardant Health’s management is scheduled to present a fireside chat on Wednesday...
Project will identify genomic and epigenomic biomarkers in patient blood samples from PICI’s RADIOHEAD study using GuardantINFINITY™ Goal of mission-focused collaboration is to help accelerate development and utilization of immune therapies for cancer Guardant He...
The data from the pivotal ECLIPSE Study accepted as a late-breaking abstract highlights the performance of the Shield ™ blood test in detecting colorectal cancer in asymptomatic patients Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is pleased ...
2023-04-20 19:57:09 ET Summary Shares of liquid biopsy genetic profiling test developer Guardant Health, Inc. have cratered 85% since achieving their all-time high of $181.07 in February 2021. Slowing top line growth, a very long timeline to profitability that includes a significa...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter of 2023 after market close on Tuesday, May 9, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific...
2023-04-18 08:59:59 ET Medicare has agreed to cover for Guardant Health's ( NASDAQ: GH ) Guardant360 Response test, which is used to assess a cancer patient's response to immune checkpoint inhibitor therapy. The blood test monitors molecular response through changes in cir...
Not intended for distribution to U.S. newswire services or for dissemination in the U.S. RED DEER, AB / ACCESSWIRE / April 17, 2023 / Gamehost Inc. ('Gamehost', the ‘Company') (TSX:GH) Gamehost has declared a cash dividend for the month of April 2023 of $0.03 (CDN) per common share, ...
News, Short Squeeze, Breakout and More Instantly...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...
2024-07-21 23:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...